Wing Yip (on behalf of Ed Arce)'s questions to Arbutus Biopharma Corp (ABUS) leadership • Q3 2024
Question
Wing Yip, asking for Ed Arce, requested clarification on the upcoming AASLD presentation for IM-PROVE II, the expected process following the Markman hearing in the Pfizer litigation, and whether the cash runway guidance includes future ATM proceeds.
Answer
Chief Medical Officer Dr. Karen Sims clarified the AASLD presentation will focus on the Group C (nivolumab cohort) data. Interim President and CEO Mike McElhaugh explained that after the December 18 Markman hearing, a written report will eventually be issued, which will help establish a court schedule. Chief Financial Officer Dave Hastings confirmed the cash runway guidance into Q4 2026 does not assume any future financing from the ATM program.